Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azimilide Long-term Safety in ICD Patients
NCT00751738Phase 3Completed
- Sponsor
- Forest Laboratories
- Start
- Oct 2002
- Primary completion
- Oct 2005
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, open-label, single-arm trial of azimilide in cardiac arrhythmia, sponsored by Forest Laboratories. Primary endpoint: Safety of azimilide at 1 year. Started Oct 2002; status: completed.
02
Drugs
azimilide
03
Conditions
cardiac arrhythmia
Beyond the preview
Go deeper on NCT00751738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00751738.